JP MORGAN/CALL/MEDTRONIC/80/0.1/17.01.25 Share Price

Warrant

DE000JB3D403

Real-time Bid/Ask 15:11:10 01/07/2024 BST
0.45 EUR / 0.46 EUR +1.11% Intraday chart for JP MORGAN/CALL/MEDTRONIC/80/0.1/17.01.25
Current month-22.41%
1 month-35.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
01/07/24 0.46 +2.22%
28/06/24 0.45 -8.16%
27/06/24 0.49 -5.77%
26/06/24 0.52 -7.14%
25/06/24 0.56 -6.67%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 07:36 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JB3D40
ISINDE000JB3D403
Date issued 07/09/2023
Strike 80 $
Maturity 17/01/2025 (200 Days)
Parity 10 : 1
Emission price 0.95
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 1.32
Lowest since issue 0.45
Spread 0.01
Spread %2.17%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
78.71 USD
Average target price
94.02 USD
Spread / Average Target
+19.46%
Consensus